Anti-MITF Polyclonal Antibody from ProteoGenix; catalogue ARO-A22129; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-MITF Polyclonal Antibody: A Powerful Tool for Studying Melanocyte Development and Melanoma Progression
The Anti-MITF Polyclonal Antibody is a highly specific and reliable tool for studying melanocyte development and melanoma progression. This antibody targets the melanocyte-specific transcription factor MITF (Microphthalmia-associated transcription factor), which plays a crucial role in the differentiation and survival of melanocytes, as well as in the development of melanoma.
MITF is a key regulator of melanocyte development and function. It controls the expression of genes involved in melanin synthesis, cell cycle progression, and cell survival. Dysregulation of MITF has been linked to various melanoma subtypes and is considered a major driver of melanoma progression.
The Anti-MITF Polyclonal Antibody is widely used in research studies to investigate the role of MITF in melanocyte development and melanoma progression. It is also a valuable tool for identifying MITF as a potential therapeutic target in melanoma treatment.
– Immunofluorescence: The Anti-MITF Polyclonal Antibody can be used in immunofluorescence experiments to visualize the expression and localization of MITF in melanoma cells. This can provide valuable insights into the role of MITF in melanoma progression and help identify potential drug targets.
– Western Blot: The antibody can also be used in western blot experiments to detect the expression of MITF in different cell types and tissues. This can help researchers understand the regulation of MITF expression and its role in melanocyte development and melanoma.
– Immunohistochemistry: The Anti-MITF Polyclonal Antibody is suitable for use in immunohistochemistry to analyze the expression of MITF in tissue samples from melanoma patients. This can provide valuable information on the correlation between MITF expression and melanoma progression.
In conclusion, the Anti-MITF Polyclonal Antibody is a powerful and versatile tool for studying melanocyte development and melanoma progression. Its high specificity and reliability make it an essential reagent for any research focused on understanding the role of MITF in melanoma. Order now and advance your research with confidence.
ProteoGenix catalogue number ARO-A22129. For research use only.
Target: Microphthalmia-associated transcription factor; Mitf; Bw; Mi; Vit; Clonality: Polyclonal Antibody; Applications: IHC, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Microphthalmia-associated transcription factor; Mitf; Bw; Mi; Vit |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
